At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, and 8 other interventions for Fallopian Tube Clear Cell Adenocarcinoma and 17 related conditions. Active but no longer recruiting, targeting 34 participants across 1 site.
Detailed Summary
This phase I/II trial studies the side effects and best dose of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) infected mesenchymal stem cells and to see how well it works in treating patients with ovarian, primary peritoneal or fallopian tube cancer that has come back. Mesenchymal stem cells may be able to carry tumor-killing substances directly to ovarian, primary peritoneal and fallopian tube cancer cells.
Study Details
Timeline
Interventions
Correlative studies
Given IP
Given IP
Undergo ECHO
Undergo MUGA
Undergo blood sample collection
Undergo chest X-ray
Undergo SPECT/CT
Undergo CT
Undergo MRI